StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Iovance Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$301.31M. For fiscal 2025 it was -$403.36M. The highest annual figure on record is -$15.77K in fiscal 2009.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$403.36M–
FY2024Dec 31, 2024-$395.28M–
FY2023Dec 31, 2023-$460.56M–
FY2022Dec 31, 2022-$398.88M–
FY2021Dec 31, 2021-$342.70M–
FY2020Dec 31, 2020-$261.94M–
FY2019Dec 31, 2019-$206.87M–
FY2018Dec 31, 2018-$128.26M–
FY2017Dec 31, 2017-$92.88M–
FY2016Dec 31, 2016-$53.64M–
FY2015Dec 31, 2015-$27.86M–
FY2014Dec 31, 2014-$12.04M–
FY2013Dec 31, 2013-$22.64M–
FY2012Dec 31, 2012-$8.13M–
FY2011Dec 31, 2011-$21.22M–
FY2010Dec 31, 2010-$815.41K–
FY2009Dec 31, 2009-$15.77K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$51.91M–
Q1 FY2026Mar 31, 2026-$81.04M–
Q4 FY2025Dec 31, 2025-$73.46M–
Q3 FY2025Sep 30, 2025-$94.90M–
Q2 FY2025Jun 30, 2025-$113.77M–
Q1 FY2025Mar 31, 2025-$121.22M–
Q4 FY2024Dec 31, 2024-$86.58M–
Q3 FY2024Sep 30, 2024-$89.07M–
Q2 FY2024Jun 30, 2024-$101.91M–
Q1 FY2024Mar 31, 2024-$117.72M–
Q4 FY2023Dec 31, 2023-$121.26M–
Q3 FY2023Sep 30, 2023-$118.36M–
Q2 FY2023Jun 30, 2023-$110.09M–
Q1 FY2023Mar 31, 2023-$110.86M–
Q4 FY2022Dec 31, 2022-$107.04M–
Q3 FY2022Sep 30, 2022-$100.40M–
Q2 FY2022Jun 30, 2022-$99.73M–
Q1 FY2022Mar 31, 2022-$91.71M–
Q4 FY2021Dec 31, 2021-$99.47M–
Q3 FY2021Sep 30, 2021-$86.24M–
Q2 FY2021Jun 30, 2021-$81.43M–
Q1 FY2021Mar 31, 2021-$75.57M–
Q4 FY2020Dec 31, 2020-$68.53M–
Q3 FY2020Sep 30, 2020-$58.97M–
Q2 FY2020Jun 30, 2020-$63.63M–
Q1 FY2020Mar 31, 2020-$70.81M–
Q4 FY2019Dec 31, 2019-$65.11M–
Q3 FY2019Sep 30, 2019-$51.61M–
Q2 FY2019Jun 30, 2019-$50.17M–
Q1 FY2019Mar 31, 2019-$39.99M–
Q4 FY2018Dec 31, 2018-$34.94M–
Q3 FY2018Sep 30, 2018-$35.06M–
Q2 FY2018Jun 30, 2018-$31.38M–
Q1 FY2018Mar 31, 2018-$26.88M–
Q4 FY2017Dec 31, 2017-$26.07M–
Q3 FY2017Sep 30, 2017-$22.34M–
Q2 FY2017Jun 30, 2017-$23.58M–
Q1 FY2017Mar 31, 2017-$20.88M–
Q4 FY2016Dec 31, 2016-$15.92M–
Q3 FY2016Sep 30, 2016-$18.98M–

More Iovance Biotherapeutics figures

See a number that looks wrong?